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BACKGROUND: Transforming growth factor (TGF)-β1 has a pivotal role in liver fibrogenesis. Curcumin effectively prevent the progression 
of liver fibrosis through inhibition of TGF-β1/Sma and 
drosophila MAD (Smad) signaling pathway. However, the 
role of curcumin in the regression of liver fibrosis is still 
unknown. This study investigated the role of curcumin and 
TGF-β1 in liver fibrosis regression. 
METHODS: An experimental Wistar rat model included 
6 treatment groups as well as positive and negative control 
groups. The treatment and positive control groups were 
injected with carbon tetrachlorid (CCl4) for 9 weeks to 
induce  liver  fibrosis.  After  cessation  of  injection, 3 of  the 
treatment  groups  were  given  curcumin  and 3 were given 
carboxymethylcellulose (CMC) for 2, 5 and 9 weeks, while 
the positive control was untreated. The negative control 
was injected with normal saline. TGF-β1 liver tissue levels 
were analyzed by ELISA, while the TGF-β1 expression in 
liver cells was analyzed by immunohistochemical assay. 
The metavir  score  was  used  to  assess  the  degree  of 
liver fibrosis. Values of p<0.05 were regarded as statistically 
significant.  
RESULTS: Nine weeks of CCl4 injection induced liver 
fibrosis (metavir F3); and significantly increased TGF-β1 
levels and expression in tissues (p=0.00, p=0.021, 
respectively). Curcumin administration decreased levels and 
expression of TGF-β1 in the liver and accelerated regression 
of liver fibrosis. There was a significant correlation between 
duration of administration of curcumin with an expression 
of  TGF-β1 in the liver tissue (r=0.87; p<0.00).
CONCLUSION: Curcumin accelerates regression of liver 
fibrosis, likely through decreasing of TGF-β1 expression in 
the liver.
KEywORDS: curcumin, TGF-β1, liver fibrosis regression, 
CCl4, animal model
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Abstract
Introduction
Regardless of the etiology, there is clinical evidence that 
the liver fibrosis may regress when its etiology is removed.
(1) Inhibition of transforming growth factor (TGF)-β 
signaling by administering an anti-TGF-β agent is one of 
the strategies in liver fibrosis treatment.(2) However, the 
role of TGF-β in the regression of liver fibrosis when its 
etiology is removed is still not widely known. TGF-β has a 
pivotal role in the process of liver fibrogenesis, from acute 
inflammation of the liver to chronic liver disease, through 
modulation of the inflammatory process. TGF-β is also 
involved in the process of liver carcinogenesis.(3,4) In liver 
fibrogenesis, TGF-β triggers the trans-differentiation of 
hepatic stellate cells (HSCs) to myofibroblast-like cells and 
thus mediates progression of liver fibrosis. Activation of the 
TGF-β1 pathway by interleukin (IL)-6/signal transducer and 
activator of transcription (Stat)3 inhibits HSC apoptosis, 
increases HSC activation and aggravates fibrosis.(5)
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 Curcumin has been extensively studied as an anti-
fibrosis agent. Curcumin inhibited liver fibrosis and blocked 
HSC activation in vitro and in vivo.(6) The mechanism 
of curcumin as an anti-fibrosis agent associated with 
TGF-β has also been widely studied. Curcumin may be 
an effective anti-fibrotic drug in the prevention of liver 
disease progression; curcumin significantly attenuated 
the severity of carbon tetrachlorid (CCl4)-induced liver 
inflammation and fibrosis through inhibition of the TGF-β1/
Sma and drosophila MAD (Smad) signaling pathway.(7,8) 
In acute liver injury, curcumin may protect against oxidative 
stress and inflammation by inhibition of TGF-β1/Smad3 
pathways.(9) However, the roles of curcumin and TGF-β in 
the regression of liver fibrosis are still unknown. We have 
therefore evaluated the ability of curcumin to cure CCl4-
induced liver fibrosis in animal models and investigated the 
level and expression of TGF-β1 in this model.
Methods
Animal
This study was an in vivo experimental study using rats 
(Rattus novergicus, Wistar strain) with a post-test control 
group and complete randomized design. The inclusion 
criteria of the animal subjects were male, 150-250 g 
body weight, and in healthy condition. All experimental 
procedures were approved by the institutional and local 
committee on the care and use of animals of Brawijaya 
University School of Medicine, Malang, East Java, 
Indonesia (No. 76/EC/KEPK/03/2016).
Figure 1. Flowchart of study and research methods. CCl4: carbon tetrachlorid; CMC: 
carboxymethylcellulose; IP: intraperitoneal. 
Development of Liver Fibrosis Models
There were 8 groups in total, including 6 groups as treatment 
groups and 2 groups as controls. The treatment groups 
include the treatment of curcumin (Tc) and treatment of 
carboxymethylcellulose (CMC) as vehicle (Tv). The control 
groups include negative control (C-) and positive control 
(C+). Each group consisted of 4 rats. The treatment groups 
and  C+  were  injected  intraperitoneally  2  times/week 
with CCl4  10%  (CCl4  dissolved  in  corn  oil  with  a  ratio 
of  1: 9), 1 cc/kgBW for 9 weeks to induce liver fibrosis. 
The C- received a normal saline injection, 1 cc/kgBW, 
twice/week for 9 weeks (see flowchart in Figure 1).  Both 
of controls were untreated after the initial 9-week injection 
cycle. A metavir score was used to assess the level of liver 
fibrosis. The C- and C+ groups were sacrificed within 72 
hours after the cessation of injection. 
Curcumin Treatment in Liver Fibrosis Models
After cessation of CCl4 injection, three groups were given 
curcumin 94% purity (#820354.0010, MERCK, Schuchardt, 
Germany), for 2 weeks (Tc2), 5 weeks (Tc5) and 9 weeks 
(Tc9). The dose of curcumin was 200 mg/kgBW/day, by 
sonde. Three groups (the CMC groups) were given just the 
solvent, CMC 1% by sonde, for 2 weeks (Tv2), 5 weeks 
(Tv5) and 9 (Tv9) weeks. All animal models in the treatment 
groups were sacrificed after 72 hours of curcumin or CMC 
administration.
Histological Examination
Liver specimens were preserved in 10% neutral buffered 
formalin solution for 24 hours and washed with 70% ethanol. 
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Tissues were then placed in small metal caskets, stirred by 
a magnetic stirrer, dehydrated using an alcohol series from 
70% to 100% alcohol, and embedded in paraffin using an 
embedding machine. Paraffin blocks were sectioned using 
a rotary ultramicrotome, distributed onto glass slides and 
then dried overnight. Slides were observed under a light 
microscope after being stained with hematoxylin and eosin 
(H&E).
Enzyme-linked Immunosorbent Assay (ELISA)
The analysis of level TGF-β1 in liver tissue was measured by 
using an ELISA kit (Biolegend, San Diego, USA) according 
to the manufacturer instructions. Briefly, liver extracts were 
prepared by homogenizing 200 mg liver tissue in 2 mL of 
buffer phosphate 0.1 M pH 7.0 and 500 µL of trichloroacetic 
acid (TCA) 10% using micropestle dan homogenizer. The 
supernatants were collected after centrifugation at 10000 
rpm for 10 minutes at 4°C and used for TGF-β1 ELISA. 
The concentration in each sample well was determined 
by interpolation from a standard curve. The analysis of 
TGF-β1 level was conducted at the Physiology Laboratory 
of  Brawijaya University School of Medicine.
Immunohistochemistry
The analysis of TGF-β1 expression in liver tissue was 
measured by immunohistochemical kits Anti TGF-β1 (No. 
BS series 0086R, Elabscience, Singapore, Singapore) and 
Secondary Antibodies (ScyTek, Utah, USA). The hot spot 
method was used to calculate the expression of TGF-β1 in 
all brown-colored liver cells. The picture was taken using 
the 40x objective. Ten shots were taken on each slide, then 
the average of the brown colored liver cells per slide was 
calculated to obtain a measure of the expression of TGF-β1 
in the liver tissue. The expression measurements of TGF-β1 
in liver tissue were performed in Pathology Anatomy 
Laboratory of Brawijaya University School of Medicine. 
Statistical Analysis
The data were analyzed using a statistical analysis program, 
IBM Statistical Products and Service Solutions (SPSS) 
Statistics, version 22.0 for Windows. A 95% confidence 
interval (α=0.05) was used as a decision threshold for 
significance. If the distribution and variant data were 
normally distributed with homogenous variability, the data 
were analyzed using statistical parametric analysis using 
one-way ANOVA; a Tukey Test for post-hoc multiple 
comparisons was used to calculate the differences between 
groups. Non-parametric analyses, namely the Kruskal-
Wallis and Mann-Whitney tests, were used when the data 
did not fulfill the assumptions of normal distribution and 
homogenous variability. A Pearson Correlation test was 
done to the relationship between duration treatment and 
levels of TGF-β1. Differences between two variables were 
calculated  with  an  independent  T-test  or  Mann-Whitney 
test.
Results
The mean body weight of rats at the beginning of the study 
was 181.56±15.46 g, while the mean body weight of rats 
at the end of the study was 229.87±35.06 g. The average 
increase in body weight was 48.31 ± 23.91 grams (data not 
shown).
 The degree of liver fibrosis was measured using 
metavir score. Figure 2 shows the H&E staining results, 
whereas Figure 3 shows the median metavir scores for each 
treatment. As seen in Figure 3, the injection of 1 cc/kgBW 
CCl4 intraperitoneally twice a week for 9 weeks (see e.g., 
group C+) produced stage F-3 of liver fibrosis (portal-central 
septae fibrosis). The negative control group, which received 
an injection of NaCl twice a week for 9 weeks (C-) had an 
F-0 score for liver fibrosis. The degree of liver fibrosis in 
curcumin groups was less than the CMC groups for 2, 5 
and 9 weeks, although not statistically significant. When 
compared to C+ and Tc9, there was a significant difference 
(p=0.001).
 The level of TGF-β1 in liver tissue in the C+ group 
was significantly higher than C- (p=0.000). Based on the 
duration of curcumin administration, the level of TGF-β1 
in liver tissue also decreased significantly for 2 weeks 
administration (p=0.021), but the TGF-β1 level then 
significantly increased in week 5 and stabilized in week 9 
(Figure 4A). The same pattern also occurred in the groups 
that were given CMC. 
 The treatment groups were administered curcumin 
had lower levels of TGF-β1 in liver tissue than the control 
groups that were given CMC. When compared over time 
separately (week 2, week 5 and week 9), the level of liver 
tissue of TGF-β1 in groups given curcumin was significantly 
lower than that those given CMC, p=0.041, p=0.000 and 
p=0.008, respectively (data not shown).
 As seen in Figure 4B, the expression of TGF-β1 in 
C+ was significantly higher than C-. Administration of 
curcumin significantly decreased the TGF-β1 expression, 
especially in Tc2 (p=0.021)and Tc5 (p=0.020). Figure 5 
shows an example photograph of immunohistochemical 
staining of TGF-β1 expression in the liver tissue.   
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Figure 2. Photomicrographs of liver tissues of rats (H&E staining). A: C-, treated with normal saline; B: C+, treated with CCl4; C: 
Tv2, treated with CCl4 + vehicle 2 weeks; D: Tc2, treated with CCl4 + curcumin 2 weeks; E: Tv5, treated with CCl4 + vehicle 5 weeks; F: 
Tc5, treated with CCl4 + curcumin 5 weeks; G: Tv9, treated with CCl4 + vehicle 9 weeks; H: Tc9, treated with CCl4 + Curcumin 9 weeks. 
White bar: 10 µm. C-: negative control; C+: positive control; Tc: curcumin treatment group; Tv: carboxymethylcellulose treatment group.
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Figure 3. Degree of fibrosis based on metavir 
score (data presented in median). C-: negative 
control; C+: positive control; Tc: curcumin 
treatment group; Tv: carboxymethylcellulose 
treatment group.
  Interestingly, the expression of TGF-β1 in Tc2 
had a similar level with the expression of TGF-β1 in C-. 
This means that the administration of curcumin for 2 weeks 
can restore the degree of fibrosis as well as the condition 
in the negative group (normal condition). Thereafter, 
the expression of TGF-β1 in curcumin groups gradually 
increased over time. Interestingly, the expression of TGF-β1 
in Tc9 was still significantly lower than the expression of 
TGF-β1 in C+ (p=0.02).
 As also seen in Figure 4B, the expression of TGF-β1 
in groups given CMC increased at week 2 (Tv2), week 
5 (Tv5) and declined at week 9 (Tv9). The expression 
of TGF-β1 at week 9 (Tv9) was almost the same as the 
expression of TGF-β1 in Tc9 (p=0.703). Based on the 
treatment, the expression of TGF-β1 in the curcumin groups 
was significantly decreased compared to the CMC groups, 
especially in week 2 and week 5 (p=0.021 and p=0.020, 
respectively).
 In the correlation analysis, there was a significant 
correlation between duration of administration of curcumin 
with an expression of TGF-β1 in the liver tissue, r=0.865; 
p=0.000 (Figure 6). This means there is an increase in 
expression of TGF-β1 along with the duration of curcumin 
administration. Whereas there was no correlation between 
duration administration of curcumin and decrease of 
TGF-β1 in liver tissue (data not shown). 
Discussion
This study may be the first research that explores the role of 
curcumin as a curative therapy for liver fibrosis, in which 
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Figure 4. The level (A) and expression 
(B) of TGF-β1 in the liver tissue. TGF: 
Transforming growth factor; C-: negative 
control; C+: positive control; Tc: curcumin 
treatment group; Tv: carboxymethylcellulose 
treatment group.
Figure 5. Immunohistochemical staining results in C+. Blue 
arrow: normal hepatocyte; Red arrow: expression of TGFβ-1 in 
hepatocyte; White arrow: normal hepatic stellate cell; Green arrow: 
expression of TGFβ-1 in hepatic stellate cell; White bar: 100 µm. 
curcumin was given in rat with liver fibrosis conditions after 
its etiology has been removed. 
 The CCl4 liver fibrosis model is the toxic model of 
liver fibrosis induction most commonly used worldwide. 
The mechanism of CCl4-induced liver fibrosis has been 
studied and the best administration route is the application 
via CCl4 intraperitoneal injection.(10,11) The duration of 9 
weeks of CCl4 administration was determined as sufficient 
in a preliminary study. In our study, CCl4 injection for 9 
weeks, 2 times/week, intraperitoneally produced an F-3 
stage of liver fibrosis (metavir score). 
 HSCs and TGF-β1 have a central role in liver 
fibrogenesis. TGF-β1 is a key member of the TGF-β 
superfamily, playing a critical role in the development of 
liver fibrosis, while HSC activation and trans-differentiation 
into myofibroblasts are believed to be the key events in 
liver fibrogenesis. TGF-β1 participates in every step of 
HSC activation. TGF-β1 triggers phenotypical trans-
differentiation of HSCs from quiescence HSC to activated 
HSC (myofibroblast-like cells) by paracrine and autocrine 
action. Stat3 activation modulates connective tissue growth 
factor (CTGF) production upon TGF-β1 challenge in 
activated HSCs.(5,12)
 High levels of TGF-β as a consequence of chronic 
liver damage also lead to massive hepatocyte cell death, 
which contributes to the promotion of the development of 
NASH, liver fibrosis and hepatocellular carcinoma.(4,13,14) 
Induction of CCl4 through intraperitoneal injection for 9 
weeks causes a chronic inflammatory process and results in 
 57
Curcumin Effect on Regression of Liver Fibrosis (Supriono, et al.)Indones  Biomed J. 2019; 11(1): 52-8DOI: 10.18585/inabj.v11i1.463
y=-2.61+2.62x
p=0.000*
R=0.863
25
20
15
10
5
0
Ex
pr
es
sio
n 
of
 T
G
Fβ
1 
(c
el
ls)
Duration of curcumin treatment (weeks)
2 4 6 8
Figure 6. The correlation of duration curcumin administration 
with the expression of TGF-β1 in liver tissue.
liver fibrosis. In our study, there was a significant increase 
of TGF-β1 expression in liver tissue after 9 weeks of CCl4 
intraperitoneal injection (Figure 4B). This helps to explain 
how important the role of TGF-β1 is in the process of liver 
fibrogenesis. 
 HSCs have a critical role in the pathogenesis of liver 
fibrosis, therefore inhibition of HSC activation and induction 
of HSC apoptosis has become potentially important for 
the prevention or treatment of liver fibrosis. It has been 
suggested that curcumin may be safely used to treat liver 
fibrosis by several different mechanisms. Curcumin not only 
inhibits HSC proliferation and transformation of HSC to an 
activated phenotype, but curcumin also induces apoptosis 
of HSC. Apoptosis of HSC will reduce secretion of type 
I collagen and production of TGF-β.(15,16) In our study, 
after the injection of CCl4 for 9 weeks resulted in a stage F3 
degree of liver fibrosis, curcumin administration accelerated 
regression of liver fibrosis for all lengths of administration.
Interestingly, at 9 weeks of administration, the curcumin 
appeared to decrease the degree of liver fibrosis significantly 
(Figure 3).
 We have shown here that treatment with curcumin 
significantly decreased of level of expression of TGF-β1 
in the liver tissue, especially in week 2 (Figure 4B). The 
expression of TGF-β1 in liver tissue at week 2 (Tc2) was 
significantly decreased, approaching the expression of 
TGF-β1 basal (C-) although increasing again in the Tc5 and 
Tc9 groups. 
 Thus, curcumin appears to reduce expression of 
TGF-β1 optimally in liver tissue after administration for 2 
weeks. Decreases of TGF-β1 levels were correlated to the 
reduction of liver fibrosis degree in week 2. The degree of 
liver fibrosis in the second week after the administration 
of curcumin was metavir score F1.5 (Figure 3). Likely, 
curcumin’s significant attenuation of the severity of CCl4-
induced liver inflammation and fibrosis was through 
inhibition of TGF-β1/Smad signaling pathway and CTGF 
expression.(7, 12) 
 As noted above, the administration of curcumin 
increased the expression of TGF-β1 gradually at 5 and 
9 weeks, but was still significantly lower than without 
curcumin  administration  (CMC  groups)  in  the week  5 
and became the same in week 9 (Figure 4B). Suppression 
of TGF-β1  by  curcumin  during  that  time  period  was 
used to accelerate the regression of liver fibrosis. The results 
correlated with the degree of liver fibrosis in this study, 
where  the  degree  of  liver  fibrosis  in  the  curcumin 
group was   lower   than   without   curcumin   administration 
(Figure 3).
 It is interesting that in the CMC groups there was also 
an increase of TGF-β1 expression. The increase was seen 
in week 2 and reached a peak in week 5 and decreased in 
week 9. It is suspected that the increase of TGF-β1 was 
needed for the regeneration process in the resolution of 
liver fibrosis. During the course of chronic liver disease 
progression, various phases occur, such as initiation, 
regeneration, perpetuation, fibrogenesis, tumorigenesis, and 
metastasis. Depending on the specific disease stage, TGF-β 
may have beneficial outcomes, especially in the initiation 
and regeneration phases.(17)
 In the initiation phase of response to liver injury, TGF-β 
enhances hepatocyte damage and induce HSC activation 
to mediate liver tissue wound healing. This initial phase 
can heal the damaged liver tissue when the inflammatory 
process is not continuous and prolonged. In the regeneration 
phase, there is a proliferation of hepatocytes, which is also 
controlled by TGF-β.(17) TGF-β signaling that controls the 
proliferation of hepatocyte is particularly mediated through 
β2-Spectrin (β2SP). The spatial expansion of β2SP may 
activate hepatic progenitor cells that regulate hepatocyte 
proliferation.(18)
 There was a significant correlation between the 
duration of curcumin administration and the expression of 
TGF-β1 in the liver tissue (Figure 6), but not in line with 
our prior expectations. Our expectations were that long-
term curcumin administration may further lower the levels 
of TGF-β1. However, long-term curcumin administration 
resulted in a higher level of TGF-β1 expression. The 
optimal TGF-β1 expression reduction was achieved at week 
2 of curcumin administration. Further research is needed to 
elucidate these results.
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Conclusion
As a curative treatment, curcumin may accelerate regression 
of liver fibrosis may through the decrease of TGF-β1.
Further research is needed to explain these mechanisms in 
more detail.
1.  Ellis EL, Mann DA. Clinical evidence for the regression of liver 
fibrosis. J Hepatol. 2012; 56: 1171-80.
2. Breitkopf K, Haas S, Wiercinska E, Singer MV, Dooley S. Anti-TGF-
beta strategies for the treatment of chronic liver disease. Alcohol 
Clin Exp Res. 2005; 29: 121S-31S.
3. Yoshida K, Murata M, Yamaguchi T, Matsuzaki K. TGF-β/Smad 
signaling during hepatic fibro-carcinogenesis. Int J Oncol. 2014; 
45: 1363-71.
4. Fabregat I, Moreno-Caceres J, Sanchez A, Dooley S, Dewidar B, 
Giannelli G, et al. TGF-β signaling and liver disease. FEBS J. 2016; 
283: 2219-32.
5. Xu MY, Hu JJ, Shen J, Wang ML, Zhang QQ, Qu Y, et al. Stat3 
signaling activation crosslinking of TGF-β1 in hepatic stellate cell 
exacerbates liver injury and fibrosis. Biochim Biophys Acta. 2014; 
1842: 2237-45.
6. Wu P, Huang R, Xiong YL, Wu C. Protective effects of curcumin 
against liver fibrosis through modulating DNA methylation. Chin J 
Nat Med. 2016; 14: 255-64.
7. Yao QY, Xu BL, Wang JY, Liu HC, Zhang SC, Tu CT. Inhibition 
by curcumin of multiple sites of the transforming growth factor-
beta1 signaling pathway ameliorates the progression of liver fibrosis 
induced by carbon tetrachloride in rats. BMC Complement Altern 
Med. 2012; 12: 156. doi: 10.1186/1472-6882-12-156.
8. Chen N, Geng Q, Zheng J, He S, Huo X, Sun X. Suppression of the 
TGF-β/Smad signaling pathway and inhibition of hepatic stellate 
References
cell proliferation play a role in the hepatoprotective effects of 
curcumin against alcohol-induced hepatic fibrosis. Int J Mol Med. 
2014; 34: 1110-6.
9. Peng X, Dai C, Liu Q, Li J, Qiu J. Curcumin attenuates on carbon 
tetrachloride-induced acute liver injury in mice via modulation of 
the Nrf2/HO-1 and TGF-β1/Smad3 pathway. Molecules. 2018: 23: 
E215. doi: 10.3390/molecules23010215.
10. Boll M, Weber LWD, Becker E, Stampfl A. Mechanism of carbon 
tetrachloride-induced hepatotoxicity. Hepatocellular damage by 
reactive carbon tetrachloride metabolites. Z Naturforsch C. 2001; 
56: 649-59.
11. Scholten D, Trebicka J, Liedtke C, Weiskirchen R. The carbon 
tetrachloride model in mice. Lab Anim. 2015: 49: 4-11.
12. Liu Y, Liu H, Meyer C, Li J, Nadalin S, Koenigsrainer A, et al. TGF-β 
mediated connective tissue growth factor (CTGF) expression in 
hepatic stellate cells requires Stat3 activation. J Biol Chem. 2013; 
288: 30708-19.
13. Yang L, Roh YS, Song J, Zhang B, Liu C, Loomba R, et al. 
Transforming growth factor beta signaling in hepatocytes 
participates in steatohepatitis through regulation of cell death and 
lipid metabolism in mice. Hepatology. 2014; 59: 483-95.
14. Yang L,  Inokuchi S,  Roh YS,  Song J,  Loomba R,  Park EJ,  Seki E. 
Transforming  growth  factor-β  signaling  in  hepatocytes  promotes 
hepatic  fibrosis  and  carcinogenesis  in  mice  with  hepatocyte-
specific  deletion  of  TAK1.  Gastroenterology.  2013;  144:  1042-
54.e4.
15. Kang HC, Nan JX, Park PH, Kim JY, Lee SH, Woo SW, et al. 
Curcumin inhibits collagen synthesis and hepatic stellate cell 
activation in-vivo and in-vitro. J Pharm Pharmacol. 2002; 54: 119-
26.
16. Shu JC, He YJ, Lv X, Zhao JR, Zhao J, Shen Y, et al. Effect of 
curcumin on the proliferation and apoptosis of hepatic stellate cells. 
Braz J Med Biol Res. 2009; 42: 1173-8.
17. Dooley S, ten Dijke P. TGF-β in the progression of liver disease. Cell 
Tissue Res. 2012; 347: 245-56.
18. Thenappan A, Li Y, Kitisin K, Rashid A, Shetty K, Johnson L, et al. 
Role of transforming growth factor β signaling and expansion of 
progenitor cells in regenerating liver. Hepatology. 2010; 51: 1373-
82.
